Evolus Inc

$6.63
Market Cap 431.35M
ROE 174.9%
Gross Margin 66.9%
Debt/Equity -5.7
Current Ratio 2.0
Revenue QoQ 6.7%
EPS QoQ -0.5%
F-Score 4

About

Evolus is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau ® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse ™, a collection of unique injectable hyaluronic acid (HA) gels.

Exchange
NASDAQ
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-10.08
vs median 32.28
P/B
-15.21
vs median 2.77
ROE
1.75
vs median 0.12

Lower quality - review fundamentals carefully

Small-cap company with higher volatility

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics